BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-1391. [PMID: 16729316 DOI: 10.1002/hep.21189] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 14.9] [Reference Citation Analysis]
Number Citing Articles
1 Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009;24:49-54. [PMID: 19196395 DOI: 10.1111/j.1440-1746.2008.05570.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
2 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
3 Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis. J Med Virol 2009;81:798-806. [DOI: 10.1002/jmv.21348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Park CH, Jung SW, Shin JW, Bae MA, Lee YI, Park YT, Chung HS, Park NH. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 2016;22:152-9. [PMID: 27044766 DOI: 10.3350/cmh.2016.22.1.152] [Reference Citation Analysis]
5 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
6 Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007;46:1695-1703. [PMID: 18027877 DOI: 10.1002/hep.21939] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
7 Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, Jang BK. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. Korean J Hepatol. 2009;15:179-192. [PMID: 19581770 DOI: 10.3350/kjhep.2009.15.2.179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
8 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
9 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
10 Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307-313. [PMID: 17256746 DOI: 10.1002/hep.21534] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 16.2] [Reference Citation Analysis]
11 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011;Oct 12; Epub ahead of print. [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
12 Ghany M, Liang TJ. Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. Gastroenterology 2007;132:1574-85. [DOI: 10.1053/j.gastro.2007.02.039] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 8.1] [Reference Citation Analysis]
13 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
14 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
15 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wong F, Pai R, Schalkwyk JV, Yoshida EM. Hepatitis B in pregnancy: a concise review of neonatal vertical transmission and antiviral prophylaxis. Annals of Hepatology 2014;13:187-95. [DOI: 10.1016/s1665-2681(19)30881-6] [Cited by in Crossref: 20] [Article Influence: 2.5] [Reference Citation Analysis]
17 Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol. 2008;18:19-34. [PMID: 17966115 DOI: 10.1002/rmv.554] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
18 Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int. 2011;31:206-214. [PMID: 21143368 DOI: 10.1111/j.1478-3231.2010.02416.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver. 2014;8:64-69. [PMID: 24516703 DOI: 10.5009/gnl.2014.8.1.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
20 Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. [PMID: 17178796 DOI: 10.1128/AAC.00833-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
21 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C;  Hepatitis B Virus Drug Resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. [PMID: 17596850 DOI: 10.1002/hep.21698] [Cited by in Crossref: 328] [Cited by in F6Publishing: 306] [Article Influence: 21.9] [Reference Citation Analysis]
23 Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K, Nakahara T, Ono A, Miki D, Kawaoka T, Abe H, Imamura M, Aikata H, Ochi H, Hayes CN, Akita T, Tanaka J, Chayama K. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. J Infect 2016;72:91-102. [PMID: 26515673 DOI: 10.1016/j.jinf.2015.09.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
24 Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2013;7:327-34. [PMID: 21688182 DOI: 10.1007/s12072-011-9282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22:1093-1108. [PMID: 19187869 DOI: 10.1016/j.bpg.2008.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
26 Wang Y, Xiao J, Ruan L, Zhang H, Chen M, Pu X, Shen H, Wu G. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clinica Chimica Acta 2009;408:70-4. [DOI: 10.1016/j.cca.2009.07.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
27 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24:809-833. [PMID: 20674805 DOI: 10.1016/j.idc.2010.07.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
29 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
30 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
31 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis: Hepatitis B virus natural mutation rate. J Gastroenterol Hepatol 2015;30:252-61. [DOI: 10.1111/jgh.12831] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
33 Phung TTB, Chu SV, Vu ST, Pham HT, Nguyen HM, Nguyen HD, Le NT, Nguyen DV, Truong PT, Vu VTT, Nguyen ATV. COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. Diagnostics (Basel) 2020;10:E491. [PMID: 32708399 DOI: 10.3390/diagnostics10070491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Khungar V, Han SH. A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010;9:75-90. [PMID: 20461127 DOI: 10.1007/s11901-010-0039-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
35 Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11:2293-2299. [PMID: 27313669 DOI: 10.3892/etm.2016.3230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med 2015;30:32-41. [PMID: 25589833 DOI: 10.3904/kjim.2015.30.1.32] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
37 Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007;11:761-95, viii. [PMID: 17981228 DOI: 10.1016/j.cld.2007.08.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
38 Lv J, Jin Q, Sun H, Chi X, Hu X, Yan H, Pan Y, Xiao W, Tian Z, Hou J. Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm. 2012;2012:804043. [PMID: 23304062 DOI: 10.1155/2012/804043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
39 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
40 Wong SN, Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology. 2006;44:309-313. [PMID: 16871562 DOI: 10.1002/hep.21307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
41 Tsuge M. Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection? Viruses 2021;13:1920. [PMID: 34696350 DOI: 10.3390/v13101920] [Reference Citation Analysis]
42 Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation. 2007;84:650-654. [PMID: 17876280 DOI: 10.1097/01.tp.0000277289.23677.0a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
43 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment. Liver Int 2012;32:303-10. [PMID: 22098177 DOI: 10.1111/j.1478-3231.2011.02647.x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509-520. [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
45 Sun H, Lv J, Tu Z, Hu X, Yan H, Pan Y, Xu D, Lian Z, Chi X, Niu J. Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients. Exp Biol Med (Maywood) 2013;238:1275-83. [PMID: 24085784 DOI: 10.1177/1535370213502626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 van der Poorten D, Prakoso E, Khoo TL, Ngu MC, McCaughan GW, Strasser SI, Lee AU. Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. J Gastroenterol Hepatol. 2007;22:1500-1505. [PMID: 17683493 DOI: 10.1111/j.1440-1746.2007.05093.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
47 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73. [PMID: 17988233 DOI: 10.1111/j.1365-2036.2007.03567.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
48 Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, Jeong ID, Bang SJ, Kim DH. Clinical significance of hepatitis B e antigen level easurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006; 12(41): 6693-6698 [PMID: 17075986 DOI: 10.3748/wjg.v12.i41.6693] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
49 Kim BG, Jung SW, Kim EH, Kim JH, Park JH, Sung SJ, Park BR, Kim M, Kim CJ, Lee BU, Park JH, Jeong ID, Bang S, Shin JW, Park NH. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir: Tenofovir in multidrug resistant hepatitis B. J Gastroenterol Hepatol 2015;30:1514-21. [DOI: 10.1111/jgh.12993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
50 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
51 Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25:891-898. [PMID: 17402992 DOI: 10.1111/j.1365-2036.2007.03272.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
52 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
53 Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. J Clin Pharmacol 2014;54:959-67. [PMID: 24964070 DOI: 10.1002/jcph.351] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Alazawi W, Foster GR. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis. 2008;21:508-515. [PMID: 18725801 DOI: 10.1097/qco.0b013e32830fb924] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
55 Lin M, Guo R, Ma C, Zeng D, Su Z. Manganese Breaks the Immune Tolerance of HBs-Ag. Open Forum Infect Dis 2021;8:ofab028. [PMID: 33614817 DOI: 10.1093/ofid/ofab028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014; 20(19): 5708-5720 [PMID: 24914332 DOI: 10.3748/wjg.v20.i19.5708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
57 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
58 Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 2014;6:191-9. [DOI: 10.1586/14787210.6.2.191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
59 Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34:972-981. [PMID: 21883327 DOI: 10.1111/j.1365-2036.2011.04833.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
60 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Tadokoro K, Suzuki F, Kobayashi M, Yamaguchi T, Nagano M, Egashira T, Kumada H. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. J Virol Methods. 2011;171:67-73. [PMID: 20950650 DOI: 10.1016/j.jviromet.2010.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhou X, Kuang X, Fan K, Zhang C, Deng G, Wang H, Wang Y. Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance. J Med Virol. 2012;84:1030-1036. [PMID: 22585719 DOI: 10.1002/jmv.23270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
64 Jhuang HJ, Hsu WH, Lin KT, Hsu SL, Wang FS, Chou CK, Lee KH, Tsou AP, Lai JM, Yeh SF, Huang CY. Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. Oncotarget 2015;6:7788-803. [PMID: 25762623 DOI: 10.18632/oncotarget.3050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
65 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
66 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151. [PMID: 19669299 DOI: 10.1007/s12072-008-9048-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
67 Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis 2011;11:178. [PMID: 21696601 DOI: 10.1186/1471-2334-11-178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
68 van Bömmel F, Berg T. Role of tenofovir in the treatment of chronic HBV infection. Future Virology 2008;3:207-20. [DOI: 10.2217/17460794.3.3.207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
70 Nash KL, Alexander GJ. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:444-8. [PMID: 18485825 DOI: 10.1016/S1473-3099(08)70102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
71 Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008;15:392-8. [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
72 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
73 Inada M, Yokosuka O. Current antiviral therapies for chronic hepatitis B. Hepatol Res. 2008;38:535-542. [PMID: 18452480 DOI: 10.1111/j.1872-034X.2008.00323.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Buti M, Rodríguez Frías F, Calleja JL, Jardí R, Pons F, Crespo J, Casanovas T, Enríquez J, Carnicer F, Romero M, García Bengoechea M, Prieto M, García Samaniego J, Miras M, Pérez Roldán F, Rueda M, Esteban R. [Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]. Med Clin (Barc) 2007;129:566-70. [PMID: 17988612 DOI: 10.1157/13111710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Wang Y, Xiao J, Liu L, Ye C, Shen H, Xu T, Zhu K. Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction. The Brazilian Journal of Infectious Diseases 2011;15:560-6. [DOI: 10.1016/s1413-8670(11)70251-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Kim SB, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol. 2016;31:241-247. [PMID: 26204913 DOI: 10.1111/jgh.13046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
77 Dore GJ, Guan R, Wasim Jafri SM, Sarin SV, Keeffe EB. Management of chronic hepatitis B in challenging patient populations. Liver International 2006;26:38-46. [DOI: 10.1111/j.1478-3231.2006.01375.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
78 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649 [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
79 Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection]. Korean J Hepatol 2008;14:503-12. [PMID: 19119245 DOI: 10.3350/kjhep.2008.14.4.503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
80 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
81 Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011;56:2130-2136. [PMID: 21253834 DOI: 10.1007/s10620-010-1561-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
82 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
83 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
84 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
85 Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, Lee D, Kim SE, Lee YS, Kim SH, Yang SH. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion 2011;84 Suppl 1:35-42. [PMID: 22156484 DOI: 10.1159/000333783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447. [DOI: 10.3350/kjhep.2007.13.4.447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
87 Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. Scand J Gastroenterol 2013;48:196-204. [PMID: 23194375 DOI: 10.3109/00365521.2012.722671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat. 2007;14 Suppl 1:29-36. [PMID: 17958640 DOI: 10.1111/j.1365-2893.2007.00915.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
89 Kim BK, Kwon SY, Lee CH, Choe WH, Choi HM, Koo HW. Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea. Korean J Hepatol 2009;15:25. [DOI: 10.3350/kjhep.2009.15.1.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother 2010;54:3205-11. [PMID: 20498322 DOI: 10.1128/AAC.01372-09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Shih YM, Sun CP, Chou HH, Wu TH, Chen CC, Wu PY, Enya Chen YC, Bissig KD, Tao MH. Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice. Sci Rep 2015;5:15259. [PMID: 26482836 DOI: 10.1038/srep15259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
92 Sánchez-tapias JM. Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 2008;31:120-8. [DOI: 10.1157/13116500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008;48:391-398. [PMID: 18199519 DOI: 10.1016/j.jhep.2007.09.020] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
94 Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026. [PMID: 21127728 DOI: 10.1155/2010/143026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
95 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
96 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. [PMID: 20659226 DOI: 10.1111/j.1440-1746.2010.06381.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
97 Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol 2008; 14(27): 4416-4419 [PMID: 18666338 DOI: 10.3748/wjg.14.4416] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
98 Han K, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185-9. [DOI: 10.1007/s12072-008-9068-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
99 Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-20. [PMID: 19175883 DOI: 10.1111/j.1365-2893.2008.01053.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
100 Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol. 2008;48:540-547. [PMID: 18279995 DOI: 10.1016/j.jhep.2007.12.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
101 Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim S. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. Journal of Viral Hepatitis 2010;17:171-7. [DOI: 10.1111/j.1365-2893.2009.01161.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
102 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
103 Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852-860. [PMID: 25596179 DOI: 10.1136/gutjnl-2014-308353] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
104 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
105 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91-100. [PMID: 21503940 DOI: 10.1002/hep.24361] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
106 Suh HJ, Park MK, Lee HIe, Gwak GY, Koh KC, Paik SW, Yoo BC, Lee JH. [Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. Korean J Gastroenterol 2009;53:305-10. [PMID: 19458467 DOI: 10.4166/kjg.2009.53.5.305] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepat. 2011;18:e432-e438. [PMID: 21914060 DOI: 10.1111/j.1365-2893.2011.01461.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
108 Zhao WF, Shao YL, Chen LY, Wu JH, Zhu YL, Gan JH, Xiong H. Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application. World J Gastroenterol 2010; 16(10): 1267-1273 [PMID: 20222172 DOI: 10.3748/wjg.v16.i10.1267] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Iser DM, Sasadeusz JJ. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008;23:699-706. [PMID: 18410604 DOI: 10.1111/j.1440-1746.2008.05382.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
110 Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 2008;48:923-31. [DOI: 10.1016/j.jhep.2008.02.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
111 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
112 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
113 Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Oberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803-3814. [PMID: 19564357 DOI: 10.1128/aac.00263-09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
114 Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci. 2012;57:1358-1365. [PMID: 22134785 DOI: 10.1007/s10620-011-1988-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
115 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
116 Kim MN, Park JY, Ahn SH, Kim BK, Kim SU, Kim DY, Han KH. Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. J Med Virol 2017;89:85-90. [PMID: 27357598 DOI: 10.1002/jmv.24616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
117 De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2010;2:1279-305. [PMID: 21994680 DOI: 10.3390/v2061279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
118 Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol 2014;49:1094-104. [DOI: 10.1007/s00535-013-0864-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
119 Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2012;57:221-231. [PMID: 21743991 DOI: 10.1007/s10620-011-1816-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
120 Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. J Med Virol 2011;83:953-61. [DOI: 10.1002/jmv.22025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
121 Liaw Y. Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how? Hepatology 2007;45:266-8. [DOI: 10.1002/hep.21546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
122 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
123 Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469 [PMID: 29151700 DOI: 10.3748/wjg.v23.i41.7459] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
124 Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res Clin Gastroenterol 2013;27:973-85. [PMID: 24182615 DOI: 10.1016/j.bpg.2013.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
125 Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B]. Korean J Gastroenterol 2015;65:35-42. [PMID: 25603852 DOI: 10.4166/kjg.2015.65.1.35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007;79:1811-1817. [PMID: 17935165 DOI: 10.1002/jmv.20981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
127 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
128 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 12.9] [Reference Citation Analysis]
129 Janmanchi D, Tseng YP, Wang K, Huang RL, Lin CH, Yeh SF. Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. Bioorganic & Medicinal Chemistry 2010;18:1213-26. [DOI: 10.1016/j.bmc.2009.12.038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
130 Lee YS, Chung YH, Kim JA, Kim SE, Shin JW, Kim KM, Lim YS, Park NH, Lee HC, Lee YS. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int. 2009;29:552-556. [PMID: 19323782 DOI: 10.1111/j.1478-3231.2008.01882.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
131 Nguyen T, Locarnini S, Desmond P. Changing landscape of antiviral resistance management in chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1314-7. [PMID: 18853991 DOI: 10.1111/j.1440-1746.2008.05551.x] [Reference Citation Analysis]
132 Chon YE, Jin B, Ahn SH, Kim S, Kim ND, Park JH, Nam CM, Kim KH, Hong SP, Choi SH, Kim DY, Park JY, Han KH. Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. Liver Int 2015;35:2370-83. [PMID: 25872678 DOI: 10.1111/liv.12845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, Blin P, Bregman B, Schmidely N, Roudot-Thoraval F, Zarski JP. High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients. Eur J Gastroenterol Hepatol 2010;22:1290-6. [PMID: 20964259 DOI: 10.1097/meg.0b013e32832fba4f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
134 Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology. 2007;132:1586-1594. [PMID: 17408643 DOI: 10.1053/j.gastro.2007.02.040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
135 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
136 Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 2009;50:1064-1071. [PMID: 19637288 DOI: 10.1002/hep.23145] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
137 Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus. Antimicrob Agents Chemother. 2017;61. [PMID: 28373196 DOI: 10.1128/aac.00183-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
138 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-1451. [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079] [Cited by in Crossref: 230] [Cited by in F6Publishing: 211] [Article Influence: 15.3] [Reference Citation Analysis]
139 Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE, Byun KS. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin Gastroenterol 2014;48:889-95. [PMID: 24440937 DOI: 10.1097/MCG.0000000000000066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
140 Suárez E, Gila A, Figueruela B, Chueca N, Muñoz Rueda P, Puche B, Fraga E, García F, Martín JM, Andrade RJ, Nogales C, Romero-Gómez M, Salmerón J. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. Gastroenterol Hepatol 2011;34:69-74. [PMID: 21334762 DOI: 10.1016/j.gastrohep.2010.11.003] [Reference Citation Analysis]
141 Lee S, Park JY, Kim do Y, Kim BK, Kim SU, Song K, Ku HJ, Han KH, Ahn SH. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. J Med Virol. 2016;88:1027-1034. [PMID: 26538234 DOI: 10.1002/jmv.24427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
142 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
143 Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol. 2008;80:1160-1170. [PMID: 18461609 DOI: 10.1002/jmv.21206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
144 Suppiah J, Mohd Zain R, Haji Nawi S, Bahari N, Saat Z. Drug-resistance associated mutations in polymerase (p) gene of hepatitis B virus isolated from malaysian HBV carriers. Hepat Mon. 2014;14:e13173. [PMID: 24497877 DOI: 10.5812/hepatmon.13173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
145 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
146 Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains. J Viral Hepat. 2013;20:141-148. [PMID: 23301549 DOI: 10.1111/j.1365-2893.2012.01639.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
147 Sheldon J, Sarmento E Castro R, Soriano V. [Resistance in hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:49-55. [PMID: 19100231 DOI: 10.1016/s0213-005x(08)76519-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
148 Matthews G. The management of HIV and hepatitis B coinfection. Curr Opin Infect Dis 2007;20:16-21. [PMID: 17197877 DOI: 10.1097/QCO.0b013e328012c5aa] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
149 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
150 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
151 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
152 Kim YJ, Paik SW, Sinn DH, Gwak G, Choi MS, Lee JH, Koh KC, Yoo BC. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance: Adefovir add-on in lamivudine-resistance. Journal of Gastroenterology and Hepatology 2012;27:1454-60. [DOI: 10.1111/j.1440-1746.2011.07050.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Seetharam A, Lisker-Melman M. Treatment of chronic hepatitis B: are we ready for combination therapy? Curr Gastroenterol Rep 2009;11:22-7. [PMID: 19166655 DOI: 10.1007/s11894-009-0004-8] [Reference Citation Analysis]
154 Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol. 2007;23:263-267. [PMID: 17414841 DOI: 10.1097/MOG.0b013e328049ddc1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
155 Kim J, Lee SH, Kim HS, Choi K, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B. Gut Liver 2015;9:103-8. [PMID: 25287170 DOI: 10.5009/gnl14018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
157 Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, Naswa MG, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Chayama K. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. J Gastroenterol 2016;51:1073-80. [PMID: 26943168 DOI: 10.1007/s00535-016-1189-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
158 ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47-58. [PMID: 18473475 DOI: 10.1111/j.1478-3231.2006.01374.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
159 Ahn SH, Yuen L, Han KH, Littlejohn M, Chang HY, Damerow H, Ayres A, Heo J, Locarnini S, Revill PA. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol. 2010;82:1126-1134. [PMID: 20513074 DOI: 10.1002/jmv.21844] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
160 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother. 2013;57:3369-3374. [PMID: 23650172 DOI: 10.1128/aac.00587-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol. 2013;19:195-209. [PMID: 24133659 DOI: 10.3350/cmh.2013.19.3.195] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
162 Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007;13:323-6. [DOI: 10.1002/lt.21013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
163 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010;24:413-37. [PMID: 20466277 DOI: 10.1016/j.idc.2010.01.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
164 Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14. [DOI: 10.1002/hep.22841] [Cited by in Crossref: 564] [Cited by in F6Publishing: 524] [Article Influence: 43.4] [Reference Citation Analysis]
165 Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO, Han KH. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol 2013;19:399-408. [PMID: 24459645 DOI: 10.3350/cmh.2013.19.4.399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Piroth L, Sène D, Pol S, Goderel I, Lacombe K, Martha B, Rey D, Loustau-Ratti V, Bergmann JF, Pialoux G. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS. 2007;21:1323-1331. [PMID: 17545709 DOI: 10.1097/qad.0b013e32810c8bcf] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
167 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
168 Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008;20:773-7. [PMID: 18617782 DOI: 10.1097/MEG.0b013e3282f793d6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
169 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
170 Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol 2010;22:736-40. [PMID: 19550344 DOI: 10.1097/MEG.0b013e32832e0a44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
171 Yotsuyanagi H, Koike K. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol 2007;42:329-35. [PMID: 17530355 DOI: 10.1007/s00535-007-2034-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
172 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
173 Cho YK, Cui XJ, Jeong SU, Song BC. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Antiviral Res 2014;112:8-17. [PMID: 25303802 DOI: 10.1016/j.antiviral.2014.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
174 Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim S, Yoo WD, Cho SW. Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2008;14:58. [DOI: 10.3350/kjhep.2008.14.1.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Hass HG, Bock T, Nehls O, Kaiser S. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol 2009;44:871-7. [DOI: 10.1007/s00535-009-0078-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
176 Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. Antivir Ther 2019;24:567-79. [PMID: 31799942 DOI: 10.3851/IMP3338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-e2. [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063] [Cited by in Crossref: 468] [Cited by in F6Publishing: 443] [Article Influence: 36.0] [Reference Citation Analysis]
178 Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747-755. [PMID: 18331765 DOI: 10.1016/j.jhep.2008.01.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 10.2] [Reference Citation Analysis]
179 Heipertz RA Jr, Starkey JL, Miller TG, Hu J, Isom HC. trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology 2009;388:57-67. [PMID: 19383566 DOI: 10.1016/j.virol.2009.03.018] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract 2016;2016:3435965. [PMID: 27672391 DOI: 10.1155/2016/3435965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
181 Qin B, Pei R, He T, Huang Z, Pan G, Tu C, Lu M, Chen X. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. Chin Sci Bull 2013;58:1760-6. [DOI: 10.1007/s11434-013-5770-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
182 Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol. 2009;15 Suppl 6:S13-S24. [PMID: 20037275 DOI: 10.3350/kjhep.2009.15.s6.s13] [Cited by in Crossref: 74] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
183 Devi U, Locarnini S. Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. Curr Hepatitis Rep 2012;11:55-64. [DOI: 10.1007/s11901-012-0132-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Pardo M, Bartolomé J, Carreño V. Current therapy of chronic hepatitis B. Arch Med Res 2007;38:661-77. [PMID: 17613358 DOI: 10.1016/j.arcmed.2006.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
185 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
186 Scott JD, Mcmahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009;11:28-36. [DOI: 10.1007/s11894-009-0005-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
187 Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18(47): 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
188 Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013;48:1188-1204. [PMID: 23397114 DOI: 10.1007/s00535-012-0737-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
189 Joo MK, Yeon JE, Kim JH, Jung YK, Lee SJ, Kim JH, Yim HJ, Byun KS, Park JJ, Kim JS, Bak YT. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment. Scand J Gastroenterol 2008;43:1514-21. [PMID: 18663665 DOI: 10.1080/00365520802273033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
190 Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009;44:601-7. [PMID: 19387534 DOI: 10.1007/s00535-009-0038-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
191 Kim MH, Cha CH, An D, Choi SE, Oh HB. [Performance evaluation of Abbott RealTime HBV Quantification Kit for HBV viral load by real-time PCR] Korean. J Lab Med. 2008;28:144-150. [PMID: 18458511 DOI: 10.3343/kjlm.2008.28.2.144] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. Virology 2018;525:48-61. [PMID: 30240958 DOI: 10.1016/j.virol.2018.08.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
193 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
194 Wang C, Yu S, Zhang Y, Zhang M, Lv L, Huang C, Li X, Li J, Zhang Z. Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy. Exp Ther Med 2019;17:2473-84. [PMID: 30906435 DOI: 10.3892/etm.2019.7255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
195 Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-frias F, Schapper M, Bonovas S, Esteban R. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. Journal of Hepatology 2007;47:366-72. [DOI: 10.1016/j.jhep.2007.04.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
196 Jiang Y, Li W, Yu L, Liu J, Xin G, Yan H, Sun P, Zhang H, Xu D, Niu J. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol. 2011;8:75-82. [PMID: 20921939 DOI: 10.1038/cmi.2010.37] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
197 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
198 Jia HY, Ding F, Chen JY, Lian JS, Zhang YM, Zeng LY, Xiang DR, Yu L, Hu JH, Yu GD, Cai H, Lu YF, Zheng L, Li LJ, Yang YD. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. World J Gastroenterol 2015; 21(12): 3657-3662 [PMID: 25834334 DOI: 10.3748/wjg.v21.i12.3657] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
199 Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int. 2012;32:656-664. [PMID: 22099071 DOI: 10.1111/j.1478-3231.2011.02676.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
200 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
201 King LK, Lee A, Anandacoomarasamy A. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. Intern Med J 2012;42:523-31. [PMID: 21790927 DOI: 10.1111/j.1445-5994.2011.02569.x] [Reference Citation Analysis]
202 Lindh M, Uhnoo I, Bläckberg J, Duberg A, Friman S, Fischler B, Karlström O, Norkrans G, Reichard O, Sangfeldt P, Söderström A, Sönnerborg A, Weiland O, Wejstål R, Wiström J. Treatment of chronic hepatitis B infection: An update of Swedish recommendations. Scandinavian Journal of Infectious Diseases 2009;40:436-50. [DOI: 10.1080/00365540802154769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
203 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
204 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
205 Wu B, Shen J, Cheng H. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res. 2012;12:385. [PMID: 23137013 DOI: 10.1186/1472-6963-12-385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
206 Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009;16:279-285. [PMID: 19222742 DOI: 10.1111/j.1365-2893.2009.01074.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
207 Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B]. Korean J Hepatol 2007;13:349-62. [PMID: 17898551 DOI: 10.3350/kjhep.2007.13.3.349] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. Eur J Intern Med. 2009;20:478-481. [PMID: 19712848 DOI: 10.1016/j.ejim.2008.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
209 Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW. Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. Arch Virol. 2014;159:29-37. [PMID: 23857507 DOI: 10.1007/s00705-013-1786-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
210 Revill P, Locarnini S. The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 303-24. [DOI: 10.1007/978-3-319-22330-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
211 Kim M, Jung SW, Shin JW, Park NH. The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance. Dig Dis Sci 2011;56:1215-21. [DOI: 10.1007/s10620-010-1537-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
212 Lee YS, Chung YH, Kim JA, Jin YJ, Park WH, Kim SE, Lee D, Shim JH, Kim KM, Lim YS. rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy. J Gastroenterol Hepatol. 2012;27:300-305. [PMID: 21777282 DOI: 10.1111/j.1440-1746.2011.06853.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
213 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
214 Hong SP, Shin SK, Lee EH, Kim EO, Ji SI, Chung HJ, Park SN, Yoo W, Folk WR, Kim SO. High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry. Nat Protoc 2008;3:1476-84. [PMID: 18772875 DOI: 10.1038/nprot.2008.136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
215 Malmström S, Hannoun C, Lindh M. Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J Virol Methods. 2007;143:147-152. [PMID: 17416427 DOI: 10.1016/j.jviromet.2007.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
216 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
217 Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18:e475-e481. [PMID: 21914066 DOI: 10.1111/j.1365-2893.2011.01479.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]